Neuraceq 300 MBq/mL solution for injection clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis
This study is testing a new type of imaging scan (called a PET scan) to see if it can accurately find a heart condition called cardiac AL amyloidosis. Researchers want to know if the scan can help doctors diagnose this condition more easily and quickly in adults.
For: ATTR Amyloidosis · AL Amyloidosis · Cardiac AmyloidosisSpain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Theranostic Trial Evaluating the Effects of Thiethylperazine in Patients Diagnosed with an Early Stage of Alzheimer's disease
This study is looking into a new treatment for early Alzheimer's disease. It's testing if a medicine called thiethylperazine can slow down changes in the brain linked to Alzheimer's, using special brain scans and blood tests.
For: Newly diagnosed early-to-mild dementia due to Alzheimer's DiseaseGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
This study is testing a new medicine called GSK4527226 (also known as AL101) for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and if it can help improve memory and thinking compared to a dummy treatment.
For: Alzheimer's DiseaseGermany · Netherlands · Finland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study is looking at how different amounts of the drug donanemab affect swelling in the brain (ARIA-E) and reduce amyloid — a protein linked to Alzheimer's disease. It's for adults in the early stages of Alzheimer's.
For: Neurocognitive Disorders · Central Nervous System Diseases · Neurodegenerative DiseasesItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period
This study is testing a new medicine called Bepranemab for people with early Alzheimer's disease. Researchers want to see if it's safe and helps with memory and thinking, compared to a dummy drug. It's a key step in understanding if this treatment could work.
For: Alzheimer’s DiseaseItaly · Spain · Germany